Onco360®, the nation’s leading independent specialty pharmacy, has added Augtyro™ (repotrectinib) manufactured by Bristol ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

Bristol-Myers Squibb is testing MORAb-202 in a Phase 2 trial to challenge traditional chemotherapy for platinum-resistant ...

J&J has rights to niraparib in prostate cancer, and views the drug as a successor to Zytiga, once a $2.5 billion-a-year ...

Nandita Vijayasimha, Bengaluru Monday, July 7, 2025, 08:00 Hrs [IST] ...

Amyloidosis therapeutics market was valued at US$ 2.95 billion in 2024 and is projected to hit the market valuation of US$ 6.37 billion by 2033 at a CAGR of 9.20% during the forecast period 2025–2033.

How was one of the largest U.S. advertisers able to grow within their highly competitive category? How has having an in-house ...